Can you do better than the experts in treating immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)? Using case-based vignettes, chairperson Siân Griffin, MD, PhD, and faculty members Jürgen Floege, MD, and Loreto Gesualdo, MD, will provide expert analysis regarding the value of lowering proteinuria and offer insights on applying clinical trial data to the unique challenges of managing advanced nephropathy. Learn how novel mechanisms, innovative treatments, and emerging data are achieving successful outcomes in patients with IgAN and FSGS.
13:30 - 14:30 CEST
IgAN Patient Case 1
IgAN Patient Case 2
IgAN Panel Discussion
FSGS Patient Case
Panel Discussion & Take-Home Messages
Question & Answer Session
Disclosures of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Siân Griffin, MD, PhD
Honorary Professor, Cardiff University
Department of Nephrology and Transplantation
University Hospital of Wales
Cardiff, United Kingdom
Consulting Fees: Alexion Pharma UK Ltd., Bayer, Eledon, Takeda, Travere
Jürgen Floege, MD
RWTH Aachen University Hospital
Consulting Fees: AstraZeneca, Bayer, Boehringer, Calliditas, Novartis, Omeros, Travere, Vifor
Loreto Gesualdo, MD, FERA
Full Professor of Nephrology
University of Bari Aldo Moro
Research: Abionyx, Sanofi
Consulting Fees: AstraZeneca, Baxter, Chinook, Estor, GSK, Medtronic, Mundipharma, Novartis, Pharmadoc, Roche, Sandoz, Sanofi, Travere
Other: Astellas, AstraZeneca, Estor, Fresenius, Travere, Werfen
- Megan Clem has nothing to disclose
- Cindy Davidson has nothing to disclose
- Ann Early has nothing to disclose
- Kate Nagele has nothing to disclose
- Katie Sheridan, PhD, has nothing to disclose
After participating in this educational activity, participants should be better able to:
- Improve their diagnosis of immunoglobulin A nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS)
- Discuss current treatment considerations of IgAN and FSGS
- Develop treatment plans to lower proteinuria in patients with IgAN and FSGS
- Review emerging treatment approaches for IgAN and FSGS
- Interpret emerging clinical trial data in IgAN and FSGS
This activity is designed to meet the educational needs of nephrology healthcare professionals.
Accreditation and Credit Designation Statement
In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at email@example.com.
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should claim only the credit commensurate with the extent of their participation in the activity.
Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.
This activity is supported by an independent educational grant from CSL Vifor.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction of this material is not permitted without written permission from the copyright owner.
Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Kate Nagele prior to the live event at firstname.lastname@example.org.